Clinical Trial Update: ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) [Phase 2]

View source ↗

Summary

Phase 2 study of RVT-1401 for Graves' Ophthalmopathy was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy

Drugs mentioned

• RVT-1401

Snippet

Sponsor: Immunovant Sciences GmbH | Conditions: Graves' Ophthalmopathy (GO) | Phase 2 | Status: TERMINATED | Results posted: 2022-09-22